HOME >> BIOLOGY >> NEWS
Vascular access vital to pump up tissue engineering

Palo Alto, Calif.-- March 30, 2004 -- Pathbreaking developments in tissue engineering and regenerative therapies are facilitating the design and growth of new organs in labs using biopolymer scaffolds and matrices. Analysis of potential markets for tissue engineering reveals that basic problems such as vascularity must be solved before such implants can gain acceptance as standard treatment methods.

"When a matrix or scaffold containing cells is implanted into a patient to treat large bone defects or complex organ damage, it is difficult to ensure that the implanted tissue construct has sufficient vascular access," says Technical Insights Analyst Katherine Austin." A construct can be kept alive in a bioreactor by constantly supplying it with nutrients and oxygen, but once it is implanted in the patient, it has to be well supplied by capillaries. You have to have sufficient perfusion reaching all of the cells or they'll die."

Significant research is being carried out seeking means to overcome this barrier.

Desktop organ printing based on several 3D computer aided design (CAD) processes that can 'print' tissues layer by layer is another method being tested. The components of blood vessels are laid down within the various layers and the tissue constructs grow their own capillaries when the appropriate growth factors and cells are added.

Apart from this physiological issue, another major factor that hinders acceptance of breakthrough technologies of tissue engineering as standards of practice is the reluctance of the medical community to accept them.

Physicians and surgeons are often traditionalists, and unless they approve of and use them, the products are unlikely to succeed. In fact, lack of confidence among surgeons and inadequate marketing strategies have led several products from prominent companies to fail.

Such failures make investors cautious. Investor confidence in the technology is also low since it is still so
'"/>

Contact: Julia Paulson
jpaulson@frost.com
210-247-3870
Technical Insights
30-Mar-2004


Page: 1 2

Related biology news :

1. Vascular disease and aging
2. Vascular Surgeons Test New Treatment For Abdominal Aneurysms
3. Study Links Viruses And Vascular Diseases
4. Scientists to prototype cyberinfrastructure for research and education access to ocean observatories
5. Keep genome data freely accessible
6. Oxford Journals takes bold step towards free access to research
7. ORNLs nanobiosensor technology gives new access to living cells molecular processes
8. American Society of Plant Biologists offers developing nations free access to science journals
9. Open access to Ohio research
10. Open access initiative from the Company of Biologists
11. Unemployment, access to guns among factors that turn domestic violence deadly

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Vascular access vital pump tissue engineering

(Date:3/20/2015)... Conn. , March 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... smart wallet is one of the products featured in ... March 20th at 11:00 PM EST on the DIY ... to Las Vegas , site of ...
(Date:3/17/2015)... 2015 Emotient, the leader in facial ... general availability of Emotient Analytics , the ... of facial expressions. The system analyzes videos of ... and services. It delivers audience response metrics - ... as derived from facial evidence of emotional states. ...
(Date:3/12/2015)... BERLIN , March 12, 2015 ... IAM, a standardized identity and access management (IAM) ... reliable implementation schedule. With Beta System,s new IAM ... and best practices gleaned from multiple IAM implementations ... includes the software as well as any necessary ...
Breaking Biology News(10 mins):NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
(Date:4/2/2015)... 02, 2015 InGaAs PIN photo diodes ... sensitivity and high-speed response. Marktech introduces the newest series ... can with active areas of 0.1mm, 0.3mm and 0.8mm. ... and high speed fiber modules. , Standard spectral range ... These parts offer considerable speed improvements over the current ...
(Date:4/1/2015)... , April 1, 2015  Adaptive Biotechnologies ... The Lancet Oncology showing that ... company,s next-generation sequencing-based minimal residual disease (MRD) detection ... MRD test) accurately identifies patients with diffuse large ... relapse after initial treatment, usually several months before ...
(Date:4/1/2015)... -- Emerson Ecologics is excited to announce its first ... . The conference will provide integrative healthcare practitioners with ... fulfilling practice. Scheduled for November 13-15, ... the conference will be a one-of-a-kind, "get it done" ... and leave with an action plan in hand. Highlights ...
(Date:4/1/2015)... , April 1, 2015  ValGenesis Inc., the market ... today that it has completed its Service Organization Controls ... Engagements (AICPA, Professional Standards) for the period of January ... 2014.  ... The SOC 2 examination ...
Breaking Biology Technology:Marktech Optoelectronics Announces High Speed InGaAs PIN Diode 1.7µm 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 3Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 4Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 5Emerson Ecologics Announces First Annual Conference for Integrative Healthcare Practitioners 2Emerson Ecologics Announces First Annual Conference for Integrative Healthcare Practitioners 3ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 2ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 3
Cached News: